Avacta‘s (LSE: AVCT) a clinical-stage life sciences company, and it caught the attention of investors when the share price shot up in 2020. The big hope is that it will rocket higher again someday.
Back then in the pandemic, the business developed products used for Covid-19 testing. It even managed to sell some of them. That created speculative buying for the stock.
However, even the firm’s Covid test kits weren’t enough to create overall profits for the enterprise.
Getting out of diagnostics
In September, the firm said it’s looking for a buyer for its diagnostics division. If successful, it could gain some much-needed capital. But at the same time it will kill off the revenue stream from that division.
Meanwhile, the share price chart mirrors the changing fortunes of the company. With the stock in the ballpark of 45p, it’s down around 65% this year.
The main ongoing focus of Avacta’s efforts is the development of cancer therapies. The company describes its pre|CISION technology as a “proprietary warhead delivery system”.
Operational progress
Given the large number of cancer sufferers, a war on the disease seems like an attractive proposition. Avacta’s trying to develop treatments to target the tumours themselves, while sparing harmful effects on normal tissues. Perhaps that area of operations can produce a future top-selling product and relaunch the share price.
The company delivered an update on progress with September’s interim results report. Chairman Shaun Chilton said the firm’s prioritising further investments in therapeutics, including the “acceleration” of its AVA6000 clinical trial enrolment.
AVA6000 showed a “highly encouraging” tolerability profile with “robust” initial efficacy signals in both dose-escalation arms of its Phase 1a trial.
The directors are “encouraged” by the potential of the “innovative” medicines in the Avacta pipeline. The firm’s AVA6000, AVA6103, and AVA7100 programmes are “highly differentiated pipeline assets, addressing large markets”.
Big costs, small revenues
Nevertheless, early-stage development’s an expensive and cash-consuming game. Loss-making companies like this tend to keep operations going by issuing more shares and raising extra money from shareholders. For example, Avacta did a fundraise in March to raise just over £31m.
Every issue of new shares dilutes existing holders. So if a drug development phase lasts too long, there can sometimes be little benefit left for the longest and most patient investors. That’s even if the business does eventually start earning decent money.
On top of that, treatments can fail even in the later stages of development. So those uncertainties are the biggest risks for Avacta shareholders today.
Nevertheless, the company’s been progressing its stable of potential new treatments and every passing week may take it closer to commercial success. So Avacta shares could recover at some point. But there’s a lot of risk for shareholders to carry in the meantime.
The post Down 65% in 2024, but can the Avacta (AVCT) share price ever recover? appeared first on The Motley Fool UK.
But there may be an even bigger investment opportunity that’s caught my eye:
Investing in AI: 3 Stocks with Huge Potential!
🤖 Are you fascinated by the potential of AI? 🤖
Imagine investing in cutting-edge technology just once, then watching as it evolves and grows, transforming industries and potentially even yielding substantial returns.
If the idea of being part of the AI revolution excites you, along with the prospect of significant potential gains on your initial investment…
Then you won’t want to miss this special report inside Motley Fool Share Advisor – ‘AI Front Runners: 3 Surprising Stocks Riding The AI Wave’!
And today, we’re giving you exclusive access to ONE of these top AI stock picks, absolutely free!
Get your free AI stock pick
More reading
This superstar FTSE growth stock is up 65% and there still looks huge value left in it to me
Could divestitures unlock hidden value in shares of this FTSE 100 company?
Just released: our 3 top income-focused stocks to buy before December [PREMIUM PICKS]
Up 125% in 5 years, the BAE share price has beaten Rolls-Royce. Which is better?
With P/E ratios of 7.2 and 9, I think these FTSE 100 shares are bargains!
Kevin Godbold has no position in any of the shares mentioned. The Motley Fool UK has no position in any of the shares mentioned. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.
